Article
Answering the CDMO Shortage: A New Paradigm for Drug Development
April 26, 2021 Ravi Samavedam
In this article, "Answering the CDMO Shortage: A New Paradigm for Drug Development" Daniel Dernbach, Vice President of Operations at Azzur Cleanrooms on Demand™, discusses the pharmaceutical industry's difficulties surrounding the shortage of contract manufacturing organizations (CMO) and contract development and manufacturing company (CDMO) facilities.
Read the full article featured in Drug Discovery & Development to find out answers regarding the severity of the CMO/CDMO capacity shortage, the advantages of finding a middle ground between building your own facility and outsourcing to the saturated market, and scaling out versus scaling up.
Ravi Samavedam
Ravi Samavedam joined Azzur Group in 2012 and is a Biochemical Engineer with more than 20 years of experience. Prior to his appointment to Chief Innovation Officer (CINO), Ravi served as President of Azzur Cleanrooms on Demand™ and previously was a General Manager of Azzur Boston. Ravi has been a part of technical operations, quality, and validation departments at some of the world’s foremost pharmaceutical manufacturers. He is an expert in phase-appropriate cGMP implementation, process validation, supplier management, and technology transfer. Ravi is an active member of industry and peer groups, and he is a frequent speaker at industry events.
Connect On Linkedin